We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00884247
First Posted: April 20, 2009
Last Update Posted: December 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity in GERD patients.

Condition
GERD

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Non Interventional Study to Evaluate the Effects on Quality of Life, Symptoms and Productivity in Patients With Gastroesophageal Reflux Disease (GERD) After 6 Weeks Structured Treatment in a Company Health Care Setting

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 36
Study Start Date: April 2009
Study Completion Date: June 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Company health care setting
Criteria

Inclusion Criteria:

  • Female and/or male aged > 18 years
  • Diagnosis of GERD confirmed
  • Prescription of GERD treatment or already receiving GERD treatment

Exclusion Criteria:

  • Any symptom suggesting a need for further investigation
  • Previous participation in the present study
  • Current participation in a clinical study or participation in a clinical study during the last 30 days
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00884247


Locations
Sweden
Research Site
Hälsocenter, Södertälje, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Svante Sjöstedt, MD, PhD AstraZeneca Sweden
Principal Investigator: Dan Regberg, MD AstraZeneca Sweden
  More Information

Responsible Party: Svante Sjöstedt/MC MDOTA, AstraZeneca
ClinicalTrials.gov Identifier: NCT00884247     History of Changes
Other Study ID Numbers: NIS-GSE-DUM-2009/1
First Submitted: April 17, 2009
First Posted: April 20, 2009
Last Update Posted: December 7, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
GERD
Quality of life
Structured treatment

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases